HOOK vs. JAGX, TPST, RLYB, SCYX, ASMB, MRNS, IFRX, VTVT, MNOV, and SLS
Should you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Jaguar Health (JAGX), Tempest Therapeutics (TPST), Rallybio (RLYB), SCYNEXIS (SCYX), Assembly Biosciences (ASMB), Marinus Pharmaceuticals (MRNS), InflaRx (IFRX), vTv Therapeutics (VTVT), MediciNova (MNOV), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical preparations" industry.
Jaguar Health (NASDAQ:JAGX) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations, profitability and community ranking.
Hookipa Pharma has a consensus target price of $4.67, suggesting a potential upside of 472.32%. Given Jaguar Health's higher probable upside, analysts plainly believe Hookipa Pharma is more favorable than Jaguar Health.
12.0% of Jaguar Health shares are owned by institutional investors. Comparatively, 63.9% of Hookipa Pharma shares are owned by institutional investors. 0.2% of Jaguar Health shares are owned by insiders. Comparatively, 5.8% of Hookipa Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Jaguar Health received 1750 more outperform votes than Hookipa Pharma when rated by MarketBeat users. Likewise, 89.08% of users gave Jaguar Health an outperform vote while only 69.11% of users gave Hookipa Pharma an outperform vote.
In the previous week, Jaguar Health had 5 more articles in the media than Hookipa Pharma. MarketBeat recorded 8 mentions for Jaguar Health and 3 mentions for Hookipa Pharma. Jaguar Health's average media sentiment score of 0.74 beat Hookipa Pharma's score of 0.14 indicating that Hookipa Pharma is being referred to more favorably in the news media.
Hookipa Pharma has a net margin of -88.73% compared to Hookipa Pharma's net margin of -377.95%. Jaguar Health's return on equity of -33.33% beat Hookipa Pharma's return on equity.
Jaguar Health has higher earnings, but lower revenue than Hookipa Pharma.
Jaguar Health has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.
Summary
Hookipa Pharma beats Jaguar Health on 10 of the 15 factors compared between the two stocks.
Get Hookipa Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hookipa Pharma Competitors List
Related Companies and Tools
